Lareb Intensive Monitoring

On August 1st Lareb launched its new Intensive Monitoring system. This is a new form of post-marketing surveillance developed in cooperation with the Medicines Evaluation Board (MEB) and the Royal Dutch Pharmaceutical Society (KNMP). 
This method is an addition to our regular system of spontaneous reporting. Patient’s experiences with drugs are the main focus of this system. Patients starting with the drug included in the Lareb monitoring system are selected in the pharmacy. After registration at www.larebmonitor.nl patients are sent questionnaires via e-mail with questions about adverse events occurring during treatment with the drug. The combination of using patient as reporters of adverse events and using e-mail to distribute the questionnaires makes it possible to obtain a lot of information about a drug in a short period of time.

Lareb Intensive Monitoring makes it possible to detect adverse reactions from new drugs at an early stage. The system will be an addition to our current system and is not intended to replace spontaneous reporting from doctors and pharmacists.
 
More information can be found on the Lareb Intensive Monitoring website